Department of Physiology and Pathophysiology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Biomedical Engineering, School of Medicine, School of Engineering, University of Alabama at Birmingham, 1670 University Blvd, VH G094E, Birmingham, AL, USA.
Cardiovasc Res. 2019 Feb 1;115(2):343-356. doi: 10.1093/cvr/cvy207.
The effectiveness of cell-based treatments for regenerative myocardial therapy is limited by low rates of cell engraftment. Y-27632 inhibits Rho-associated protein kinase (ROCK), which regulates the cytoskeletal changes associated with cell adhesion, and has been used to protect cultured cells during their passaging. Here, we investigated whether preconditioning of cardiomyocytes, derived from human-induced pluripotent stem cells (hiPSC-CM), with Y-27632 improves their survival and engraftment in a murine model of acute myocardial infarction (MI).
After MI induction, mice were subjected to intramyocardial injections of phosphate-buffered saline, hiPSC-CM cultured under standard conditions (hiPSC-CM-RI), or Y-27632-preconditioned hiPSC-CM (hiPSC-CM+RI). The resulting engraftment rate calculated 4 weeks after implantation was significantly higher and the abundance of apoptotic transplanted cells was significantly lower in hiPSC-CM+RI recipients than in hiPSC-CM-RI animals. In cultured hiPSC-CM, Y-27632-preconditioning reversibly reduced contractile activity and the expression of troponin genes, while increasing their attachment to an underlying mouse cardiomyocyte (HL1) monolayer. Y-27632 preconditioning also increased the expression of N-cadherin and integrin ß1, the two cell junction proteins. hiPSC-CM+RI were also larger in cell area with greater cytoskeletal alignment and a more rod-like shape than hiPSC-CM-RI, both after transplantation (in vivo) and in culture. The effects of Y-27632 preconditioning on contractile activity and morphology of hiPSC-CMs in culture, as well as on their engraftment rate and apoptotic death in MI mouse grafts, could be recapitulated by hiPSC-CM treatment with the L-type calcium-channel blocker verapamil.
Preconditioning with the ROCK inhibitor Y-27632 increased the engraftment of transplanted hiPSC-CM in a murine MI model, while reversibly impairing hiPSC-CM contractility and promoting adhesion.
细胞疗法在心肌再生中的效果受到细胞植入率低的限制。Y-27632 抑制 Rho 相关蛋白激酶(ROCK),后者调节与细胞黏附相关的细胞骨架变化,并且已被用于保护培养细胞在传代过程中的生存。在此,我们研究了用 Y-27632 预处理源自人诱导多能干细胞(hiPSC-CM)的心肌细胞是否能提高它们在急性心肌梗死(MI)小鼠模型中的存活率和植入率。
MI 诱导后,将磷酸盐缓冲盐水、在标准条件下培养的 hiPSC-CM(hiPSC-CM-RI)或 Y-27632 预处理的 hiPSC-CM(hiPSC-CM+RI)注射到心肌内。与 hiPSC-CM-RI 动物相比,植入后 4 周计算得出的植入率明显更高,并且移植的细胞凋亡明显减少。在培养的 hiPSC-CM 中,Y-27632 预处理可可逆地降低收缩活性和肌钙蛋白基因的表达,同时增加它们与底层小鼠心肌细胞(HL1)单层的附着。Y-27632 预处理还增加了细胞黏附蛋白 N-钙黏蛋白和整合素β1 的表达,这两种细胞连接蛋白。与 hiPSC-CM-RI 相比,hiPSC-CM+RI 的细胞面积更大,细胞骨架排列更整齐,呈更棒状,无论是在移植后(体内)还是在培养中。Y-27632 预处理对 hiPSC-CM 收缩活性和形态的影响,以及对 MI 小鼠移植物中植入率和凋亡死亡的影响,可通过 hiPSC-CM 用 L 型钙通道阻滞剂维拉帕米处理来重现。
用 ROCK 抑制剂 Y-27632 预处理可增加移植的 hiPSC-CM 在 MI 小鼠模型中的植入率,同时可逆性地损害 hiPSC-CM 的收缩能力并促进黏附。